Cristina
Legido-Quigley
CLQ LAB
Neuro & Metabolic Clinical Research
RESEARCH
Dr Legido-Quigley's Lab works in PanMolecular Precison Medicine, using molecules and molecular panels that are not used in rutine clinical tests to achieve personalised treatments. Her work focuses in neuro and metabolic diseases and particulalrly in disease that affects the brain and the liver, like Alzheimer's Disease and Diabetes.
The lab's science is at the interface between chemistry and medicine and her lab houses experts in biotechnology and data science to allow the detection of thousands of small molecules / lipids.
These molecules are measured with mass spectrometry instruments and then, data analytics, including machine learning, is performed to understand biology and predict disease outcomes. In order to translate results into the clinic we also work with clinical trials and evidence portfolios for EMA/FDA approval.
CLICK the illustrations below to read example press releases from our work
CLQ was awarded 4.940.250 DKK by The Lundbeck Foundation to investigate lipids and Alzheimer’s disease/Diabetes, a collaboration within Denmark and The Untited Kingdom (2021-2025)
Higher brain glucose may mean more severe Alzheimer's. (2017)
Lipidomics of human tissue reveals diversity between body areas. (2020)
Molecules in fecal samples for detecting liver disease (2022)
CLICK
TO ACCESS
PUBLICATIONS
Could sleep molecules lead to blood test for Alzheimer's Disease?. (2019)
Brain Fatty acids dysregulated in Alzheimer's Disease. (2017)
DONORS & SPONSORS
We are very grateful for the samples that volunteers and donors give us and make our research possible.
As well, we thank all our collaborators and the funding bodies and sponsors that fund our research.
CURRENT FUNDERS:
.
PREVIOUS FUNDERS OVER THE YEARS:
.
